Neurocrine Biosciences (Neurocrine Biosciences) Liabilities-to-Assets : 0.31 (As of Dec. 2023)

Neurocrine Biosciences Liabilities-to-Assets Chart

Neurocrine Biosciences Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Liabilities-to-Assets		Get a 7-Day Free Trial					0.51	0.35	0.34	0.28	0.31

Neurocrine Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Liabilities-to-Assets	Get a 7-Day Free Trial															0.28	0.29	0.29	0.30	0.31

Competitive Comparison of Neurocrine Biosciences's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neurocrine Biosciences's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Liabilities-to-Assets falls into.

Neurocrine Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Neurocrine Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Neurocrine Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences  (NAS:NBIX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Neurocrine Biosciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (Neurocrine Biosciences) Business Description